SGLT2 inhibitors in CKD
SGLT2 inhibitors to slow chronic kidney disease.
Key point
In non-diabetic CKD, renin-angiotensin system inhibitors and SGLT2 inhibitors would be indicated as the treatment of choice.
From: [SEMERGEN position paper on chronic kidney disease] (Semergen, 2026 Apr) ↗Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 32, 33, 44, 43, 52.
New guidelines and consensus this year
- ASN Kidney Health Guidance on the Cardiovascular-Kidney-Metabolic SyndromeJ Am Soc Nephrol2026 Oct 1
- [SEMERGEN position paper on chronic kidney disease]Semergen2026 Apr
All papers from the last 12 months
712 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- Irisin as a multi-target renoprotective mediator in chronic kidney disease: from molecular mechanisms to therapeutic perspectivesClin Chim Acta2027 Jan 1PMID 42303153Review
- Efficacy and mechanistic insights of dapagliflozin in hypertension managementClin Exp Hypertens2026 Dec 31PMID 42826222Review
- Multisystem effects of sodium-glucose cotransporter-2 inhibitors beyond glycaemic control: an umbrella review of systematic reviews and meta-analysesJ Diabetes Metab Disord2026 DecPMID 42856812Review
- Real-world prescribing patterns of SGLT2 inhibitors and GLP-1 receptor agonists in Type 2 diabetes with various ASCVD subtypes from a large tertiary referral centerAm J Prev Cardiol2026 DecPMID 42827863
- Circadian reprogramming of inflammation and metabolism in chronic kidney diseaseRen Fail2026 DecPMID 42703061
- SGLT2 inhibitors versus GLP-1 receptor agonists and risk of kidney replacement therapy and healthcare utilization in bipolar disorder with chronic kidney disease: An active-comparator, new-user cohort studyJ Affect Disord2026 Dec 1PMID 42632571
- SGLT2 inhibitors and chronic kidney disease: a narrative review of nephroprotective mechanisms from hemodynamics to metabolismRen Fail2026 DecPMID 42392584Review
- Clinical events and healthcare costs of dapagliflozin in adults with cardiovascular-kidney-metabolic syndrome in Spain: a cost-offset analysisJ Med Econ2026 DecPMID 42343656
- Nephrotoxic medication burden and drug-related problems in patients with chronic kidney disease using SGLT2 inhibitorsRen Fail2026 DecPMID 42336367
- Dapagliflozin improves hemoglobin and anemia in chronic kidney disease: a systematic review and meta-analysisRen Fail2026 DecPMID 42021630Meta-analysisSystematic review
More nephrology trends
All specialties →GLP-1 drugs in kidney disease
GLP-1 based medicines and kidney outcomes.
Key point: In CKD, GLP-1 receptor agonists were associated with fewer major adverse kidney events and lower albuminuria, primarily in type 2 diabetes, with gastrointestinal concerns.
Acute kidney injury biomarkers
Biomarkers to detect and predict acute kidney injury.
IgA nephropathy
IgA nephropathy and the new targeted treatments being studied.
Lupus nephritis
Kidney involvement in lupus and its newer treatments.
Key point: Lupus nephritis management is increasingly individualized, with expanding treatment options, combination therapy, and a trend toward lower corticosteroid doses.
Complement inhibitors in kidney disease
Iptacopan, avacopan and other complement inhibitors in glomerular disease.
Key point: Complement inhibitors had no overall effectiveness or safety advantage over plasma therapy in atypical hemolytic uremic syndrome, except lower relapse rates.
APOL1 kidney disease
Kidney disease linked to APOL1 gene variants.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
(SGLT2[tiab] OR dapagliflozin[tiab] OR empagliflozin[tiab] OR canagliflozin[tiab]) AND ("chronic kidney disease"[tiab] OR CKD[tiab])Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.